Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Faculty of Pharmacy, Al-Azhar University-Gaza, Gaza Strip, Palestine.
Drugs R D. 2022 Sep;22(3):187-203. doi: 10.1007/s40268-022-00398-z. Epub 2022 Aug 3.
In young people aged < 50 years, cervical artery dissection (CeAD) is among the most common causes of stroke. Currently, there is no consensus regarding the safest and most effective antithrombotic treatment for CeAD. We aimed to synthesize concrete evidence from studies that compared the efficacy and safety of antiplatelet (AP) versus anticoagulant (AC) therapies for CeAD.
We searched major electronic databases/search engines from inception till September 2021. Cohort studies and randomized controlled trials (RCTs) comparing anticoagulants with antiplatelets for CeAD were included. A meta-analysis was conducted using articles that were obtained and found to be relevant. Mean difference (MD) with 95% confidence interval (CI) was used for continuous data and odds ratio (OR) with 95% CI for dichotomous data.
Our analysis included 15 studies involving 2064 patients, 909 (44%) of whom received antiplatelets and 1155 (56%) received anticoagulants. Our analysis showed a non-significant difference in terms of the 3-month mortality (OR 0.47, 95% CI 0.03-7.58), > 3-month mortality (OR 1.63, 95% CI 0.40-6.56), recurrent stroke (OR 0.97, 95% CI 0.46-2.02), recurrent transient ischaemic attack (TIA) (OR 0.93, 95% CI 0.44-1.98), symptomatic intracranial haemorrhage (sICH) (OR 0.38, 95% CI 0.12-1.19), and complete recanalization (OR 0.70, 95% CI 0.46-1.06). Regarding primary ischaemic stroke, the results favoured AC over AP among RCTs (OR 6.97, 95% CI 1.25-38.83).
Our study did not show a considerable difference between the two groups, as all outcomes showed non-significant differences between them, except for primary ischaemic stroke (RCTs) and complete recanalization (observational studies), which showed a significant favour of AC over AP. Even though primary ischaemic stroke is an important outcome, several crucial points that could affect these results should be paid attention to. These include the incomplete adjustment for the confounding effect of AP-AC doses, frequencies, administration compliance, and others. We recommend more well-designed studies to assess if unnecessary anticoagulation can be avoided in CeAD.
在年龄<50 岁的年轻人中,颈动脉夹层(CeAD)是中风的最常见原因之一。目前,对于 CeAD 最安全、最有效的抗血栓治疗方法尚无共识。我们旨在综合比较抗血小板(AP)与抗凝(AC)治疗 CeAD 的疗效和安全性的研究中的具体证据。
我们从成立之初到 2021 年 9 月,检索了主要的电子数据库/搜索引擎。纳入了比较抗凝剂与抗血小板治疗 CeAD 的队列研究和随机对照试验(RCT)。对获得的并认为相关的文章进行了荟萃分析。使用均值差(MD)和 95%置信区间(CI)表示连续性数据,使用比值比(OR)和 95%CI 表示二分类数据。
我们的分析包括了 15 项研究,涉及 2064 名患者,其中 909 名(44%)接受了抗血小板治疗,1155 名(56%)接受了抗凝治疗。我们的分析显示,3 个月死亡率(OR 0.47,95%CI 0.03-7.58)、>3 个月死亡率(OR 1.63,95%CI 0.40-6.56)、复发性中风(OR 0.97,95%CI 0.46-2.02)、复发性短暂性脑缺血发作(TIA)(OR 0.93,95%CI 0.44-1.98)、症状性颅内出血(sICH)(OR 0.38,95%CI 0.12-1.19)和完全再通(OR 0.70,95%CI 0.46-1.06)方面无显著差异。关于原发性缺血性中风,结果显示 RCT 中 AC 优于 AP(OR 6.97,95%CI 1.25-38.83)。
我们的研究并没有显示两组之间有显著差异,因为除了原发性缺血性中风(RCT)和完全再通(观察性研究)外,所有结果之间均无显著差异,而这两项结果显示 AC 优于 AP。尽管原发性缺血性中风是一个重要的结局,但有几个可能影响这些结果的关键因素需要注意。这些因素包括 AP-AC 剂量、频率、给药依从性等混杂因素影响的不完全调整。我们建议进行更多精心设计的研究,以评估在 CeAD 中是否可以避免不必要的抗凝治疗。